A new Japanese encephalitis vaccine (Ixiaro)

Medical Letter on Drugs and Therapeutics

Volumn 51, Issue 1319, 2009, Pages 66-67

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE; IXIARO; JAPANESE ENCEPHALITIS VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; UNCLASSIFIED DRUG; INACTIVATED VACCINE;

ANTIBODY TITER; CLINICAL TRIAL; COMA; DEATH; DELAYED HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; EPIDEMIC ENCEPHALITIS; HUMAN; IMMUNOGENICITY; INFECTION RISK; INJECTION SITE REACTION; JAPANESE ENCEPHALITIS VIRUS; MENTAL DISEASE; NEUROTOXICITY; SEROCONVERSION; SHORT SURVEY; ARTICLE; DOSE RESPONSE; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; ENCEPHALITIS, JAPANESE; HUMANS; INJECTIONS, INTRAMUSCULAR; JAPANESE ENCEPHALITIS VACCINES; TREATMENT OUTCOME; VACCINES, INACTIVATED;

EID: 69849112190     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (13)

1. Advice for travelers. Treat Guidel Med Lett 2006; 4:25.
2. GD Burchard et al. Expert opinion on vaccination of travelers against Japanese encephalitis. J Travel Med 2009; 16:204.
3. Japanese encephalitis among three U.S. travelers returning from Asia, 2003-2008. MMWR Morb Mortal Wkly Rep 2009; 58:737.
4. MR Buhl and L Lindquist. Japanese encephalitis in travelers: review of cases and seasonal risk. J Travel Med 2009; 16:217.
5. E Tauber et al. Safety and immunogenicity of a Vero-cell-derived inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 2007; 370:1847.
6. CH Hoke et al. Protection against Japanese encephalitis by inactivated vaccines. New Engl J Med 1988; 319:608.
7. RF DeFraites et al. Japanese encephalitis vaccine (inactivated, BIKEN) in U.S. soldiers: immunogenicity and safety of vaccine administered in two dosing regimens. Am J Trop Med Hyg 1999; 61:288.
8. E Schuller et al. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study. Vaccine 2008; 26:4382.
9. A Kaltenböck et al. Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study. Vaccine 2009; 27:4483.
10. FDA Division of Vaccines and Related Product Applications. Clinical review of new biologics license application STN# 125280/0-Ixiaro. Available at www.fda.gov/Biologics BloodVaccines/Vaccines/ApprovedProducts/ucm142556.htm. Accessed August 17, 2009.
11. E Tauber et al. Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated japanese encephalitis vaccine. J Infect Dis 2008;198:493.
12. ACIP provisional recommendations for the use of Japanese encephalitis virus vaccines, June 24, 2009. Available at www.cdc.gov/vaccines/recs/ provisional/downloads/je-july 2009-508.pdf. Accessed August 17, 2009.
13. Picaridin - A new insect repellent. Med Lett Drugs Ther 2005; 47:46.